RxDoctor Payments Data

William Maher, MD

Gastroenterology · Somersworth, NHNPI 1477550739

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Cook Medical LLC at 29.8% of the total. Reporting peaked in 2019 at $370 and has fallen 92.2% since, to $29 in 2025. That places this record below the midpoint for gastroenterology clinicians in NH, where the typical reported total is $653.

$712in general payments, 2019–2025

Across 26 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Medical LLC$212
  • AbbVie$144
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • Intercept Pharmaceuticals, Inc.$79
  • Covidien LP$74
  • Johnson & Johnson$31
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$68797%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$712 in reported general payments places this provider in the 50th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$251,687
Medicare patients
845
Services billed
6,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$23,796
Mesalamine22$20,464
Ursodiol60$5,969
Omeprazole192$2,980
Colestipol Hcl55$2,772
Budesonide DrBudesonide13$2,650
Pantoprazole Sodium115$1,865
Famotidine166$1,213
CholestyramineCholestyramine (With Sugar)12$1,121
Sucralfate30$969
Balsalazide Disodium11$603
Lansoprazole14$470
Azathioprine12$405
Dicyclomine Hcl22$386
Spironolactone20$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$144$23,79613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Somersworth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →